Rigel Pharmaceuticals, Inc. (RIGL) earnings
RIGL earnings moved a median of -1.11% by the close. Quarterly and annual RIGL reports and results, each read against the price at its own news timestamp. Back to the RIGL overview →
30 measured RIGL earnings events.
Where these RIGL earnings landedvs 29 measured RIGL earnings reactions
| Middle 50% of RIGL earnings reactions | -6.00% to +2.72% |
|---|---|
| Median reaction (to close) | -1.11% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 RIGL earnings events with a measured close landed between -6.00% and +2.72%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q RIGEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -1.63% | -4.71% | |
| Rigel Reports Second Quarter 2026 Financial Results | Press release | -1.63% | -4.71% | |
| Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results | Press release | -0.24% | +2.72% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -2.44% | -7.07% | |
| Rigel Reports First Quarter 2026 Financial Results | Press release | -2.44% | -7.07% | |
| Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results | Press release | -0.31% | -0.42% | |
| Form 10-K RIGEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -5.12% | -2.15% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +3.56% | +8.55% | |
| Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +3.56% | +8.55% | |
| Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update | Press release | +0.67% | -1.01% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -2.54% | +9.68% | |
| Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -2.54% | +9.68% | |
| Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update | Press release | -0.65% | — | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +0.89% | -18.09% | |
| Rigel Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.89% | -18.09% | |
| Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update | Press release | +0.00% | +0.36% | |
| Form 10-K RIGEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.74% | +0.69% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +11.50% | +32.55% | |
| Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +11.50% | +32.55% | |
| Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update | Press release | +0.00% | -3.47% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +2.10% | -6.00% | |
| Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +2.10% | -6.00% | |
| Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update | Press release | +0.00% | -0.09% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -5.41% | -10.60% | |
| Rigel Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -5.41% | -10.60% | |
| Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update | Press release | +1.87% | -1.87% | |
| Form 10-K RIGEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.65% | +1.30% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -1.52% | -1.11% | |
| Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -1.52% | -1.11% | |
| Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update | Press release | +0.48% | +3.99% |
Keep exploring
More RIGL: analyst actions → · SEC filings → · RIGL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 279 | -0.52% | 36% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.